US FDA approves Kimyrsa: treatment of acute bacterial skin and skin tissue infections

Melinta Therapeutics is a pharmaceutical company focused on the development and commercialization of new antibiotics.

Kimyrsa is a single-dose long-acting lipoglycopeptide antibiotic with rapid bactericidal activity and is used to treat ABSSI in adults caused by designated Gram-positive microorganisms (including MRSA).

Kimyrsa is the first oritavancin product to be infused within 1 hour.

ABSSI affects approximately 14 million patients in the United States each year, and more than 3 million visits to the emergency room each year, making it the eighth most common reason for admission to emergency hospitals.

Kimyrsa is an important new treatment option that will provide clinicians with additional flexibility to treat ABSSI patients in a variety of care settings without the need for hospitalization.

The effectiveness and safety of Kimyrsa was confirmed in the clinical trial SOLO of another oritavancin product Orbactiv.

Original source: Melinta Therapeutics Announces FDA approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

The lead investigator of the PK clinical trial, Dr.